Monograph Details
|
|
Nutrition
> Obesity
|
|
DIDREX |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
CIII |
| Pharmacological Class |
|
Sympathomimetic. |
| Generic Name |
|
Benzphetamine HCl 50mg; scored tabs. |
| Indications |
|
Short-term adjunct in management of exogenous obesity. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 25–50mg daily in mid-morning or mid-afternoon. Increase if needed to 25–50mg 1–3 times daily. |
| Contraindications |
|
Advanced arteriosclerosis. Cardiovascular disease. Hypertension. Hyperthyroidism. Agitation. Drug or alcohol abuse. During or within 14 days of MAOIs. Pregnancy (Cat.X). |
| Precautions |
|
Discontinue after a few weeks as tolerance to anorectic effect occurs. Diabetes. Prescribe limited supply to prevent overdose. Nursing mothers: not recommended. |
| Interactions |
|
Hypertensive crisis with MAOIs. Blocks guanethidine. Altered insulin requirements. Potentiated by urinary alkalinizers. Antagonized by urinary acidifiers. |
| Adverse Reactions |
|
Abuse potential, impairment in hazardous activities, arrhythmias, hypertension, CNS overstimulation, psychosis, dry mouth, GI disturbances, urticaria, impotence. |
| How Supplied |
|
Tabs—100, 500 |
|
|
|
|
